Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40411
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEssers, B-
dc.contributor.authorVAN GILS, Annick-
dc.contributor.authorLafosse, C-
dc.contributor.authorMichielsen, M-
dc.contributor.authorBeyens, H-
dc.contributor.authorSchillebeeckx, F-
dc.contributor.authorVeerbeek, JM-
dc.contributor.authorLuft, AR-
dc.contributor.authorKOS, Daphne-
dc.contributor.authorVerheyden, G-
dc.date.accessioned2023-06-15T10:01:20Z-
dc.date.available2023-06-15T10:01:20Z-
dc.date.issued2021-
dc.date.submitted2023-06-09T12:17:21Z-
dc.identifier.citationJournal of the American College of Cardiology, 78 (21) , p. 2060 -2072-
dc.identifier.issn0735-1097-
dc.identifier.urihttp://hdl.handle.net/1942/40411-
dc.description.abstractBACKGROUND The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown. OBJECTIVES The purpose of this analysis was to compare 1 vs 3 months of DAPT in HBR patients undergoing drug eluting stent implantation. METHODS The XIENCE Short DAPT program comprised 3 prospective, multicenter, single-arm studies of HBR patients treated with a short DAPT course followed by aspirin monotherapy after PCI with a cobalt-chromium everolimus-eluting stent. In this exploratory analysis, patients who received 1-month DAPT (XIENCE 28 USA and 28 Global) were compared with those on 3-month DAPT (XIENCE 90) using propensity score stratification. Ischemic and bleeding outcomes were assessed between 1 and 12 months after index PCI. RESULTS A total of 3,652 patients were enrolled and 1,392 patients after 1-month DAPT and 1,972 patients after 3 month DAPT were eligible for the analyses. The primary endpoint of all-cause mortality or myocardial infarction was similar between the 2 groups (7.3% vs 7.5%; difference-0.2%; 95% CI:-2.2% to 1.7%; P = 0.41). The key secondary endpoint of BARC (Bleeding Academic Research Consortium) type 2-5 bleeding was lower with 1-month DAPT compared with 3-month DAPT (7.6% vs 10.0%; difference-2.5%; 95% CI:-4.6% to-0.3%; P = 0.012). Major BARC type 3-5 bleeding did not differ at 12 months (3.6% vs 4.7%; difference-1.1%; 95% CI:-2.6% to 0.4%; P = 0.082), but was lower with 1-month DAPT at 90 days (1.0% vs 2.1%; P = 0.015). CONCLUSIONS Among HBR patients undergoing PCI, 1 month of DAPT, compared with 3 months of DAPT, was associated with similar ischemic outcomes and lower bleeding risk. (XIENCE 90 Study; NCT03218787; XIENCE 28 USA Study; NCT03815175; XIENCE 28 Global Study; NCT03355742) (J Am Coll Cardiol 2021;78:2060-2072) (c) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.rights2021 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) .-
dc.subject.otherbleeding-
dc.subject.othereverolimus-eluting stent-
dc.subject.otherhigh bleeding risk-
dc.subject.othershort DAPT-
dc.subject.otherthrombosis-
dc.titleDuration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI-
dc.typeJournal Contribution-
dc.identifier.epage2072-
dc.identifier.issue21-
dc.identifier.spage2060-
dc.identifier.volume78-
local.format.pages13-
local.bibliographicCitation.jcatA1-
local.publisher.placeSTE 800, 230 PARK AVE, NEW YORK, NY 10169 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.jacc.2021.08.074-
dc.identifier.pmid34794687-
dc.identifier.isi000720068300005-
dc.identifier.eissn1558-3597-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.contributorEssers, B-
item.contributorVAN GILS, Annick-
item.contributorLafosse, C-
item.contributorMichielsen, M-
item.contributorBeyens, H-
item.contributorSchillebeeckx, F-
item.contributorVeerbeek, JM-
item.contributorLuft, AR-
item.contributorKOS, Daphne-
item.contributorVerheyden, G-
item.accessRightsOpen Access-
item.fullcitationEssers, B; VAN GILS, Annick; Lafosse, C; Michielsen, M; Beyens, H; Schillebeeckx, F; Veerbeek, JM; Luft, AR; KOS, Daphne & Verheyden, G (2021) Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. In: Journal of the American College of Cardiology, 78 (21) , p. 2060 -2072.-
item.validationecoom 2023-
item.fulltextWith Fulltext-
crisitem.journal.issn0735-1097-
crisitem.journal.eissn1558-3597-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0735109721063191-main.pdfPublished version1.22 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.